Orphan Drug Catalyst on Tap For DARA

Print E-mail
By Scott Matusow, @scottmatusow   
Tuesday, 19 February 2013 06:52

icon_SectorWatchDARA Biosciences (NASDAQ: DARA), a specialty pharmaceutical company focused on oncology and oncology supportive care products, is expecting to hear soon on the status of its Orphan Drug application submitted to The Food and Drug Administration

(FDA) in November of last year for its drug KRN5500, which is being studied for the treatment of chronic chemotherapy-induced peripheral neuropathy (CCIPN).

KRN5500 is a novel, spicamycin-derived, non-opioid-non-narcotic intravenous pain therapeutic with promising clinical trial results in patients with chemotherapy-induced peripheral neuropathy (CIPN)

More than 70% of patients treated with taxane-class or platinum-class chemotherapeutic agents; at least 25% of those treated with vinca-class agents; and significant numbers of those treated with Thalomid®, Revlimid®, Velcade®, and a variety of other cancer drugs experience CIPN, which can be disabling and adversely affect quality of life.

There is presently no FDA-approved drug for CIPN.

In October, 2011, the U.S. FDA granted KRN-5500 Fast Track designation for CIPN, an indication with a market potential estimated at $2.5B.

Summary of Phase 2a clinical trial results:

  • "A Spicamycin Derivative (KRN5500) Provides Neuropathic Pain Relief in Patients with Advanced Cancer: A Placebo-Controlled, Proof-of-Concept Trial"; Journal of Pain and Symptom Management http://digitalreprints.elsevier.com/issue/47166.
  • Patients had failed on at least two previous pain therapeutics
  • KRN5500 met primary endpoints: reduction of pain and safety
  • Significantly more effective than placebo (p=0.03)
  • Transient and manageable GI side effects

The stock is trading in a manner that hints at positive news concerning the Orphan Drug status application.

The above chart is forming a cup and handle breakout pattern with resistance at $1.20. Once past this level, the near term price target indicates a test of the prior high of $1.38. Measuring the cup and handle break indicates a move over $2 in the coming months. I predicted a move to $0.98 on my live online show as a good entry point before beginning to break out -- The price hit $0.97, and then began to move back upwards. I am setting a price target opinion of $1.35 to $1.45 for the short term.

Disclosure: Author Scott Matusow is Long DARA.





BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter

BioMedReports Agios Pharma Reports Initiation of Phase 1/2 Clinical Trial of AG-221; Pluristem Advances its Second Major Cel... http://t.co/qkvJGEUaT5
6hreplyretweetfavorite
BioMedReports Active Stocks: MELA Sciences, Synergy Pharmaceuticals, Omeros, Novartis, Enanta Pharmaceuticals: U.S. stocks ... http://t.co/HvHIdi6Bgg
10hreplyretweetfavorite
BioMedReports CytRx Announces Publication of Phase 1b/2 Aldoxorubicin; NewLink Genetics Announces Licensing Agreement For De... http://t.co/l9LvyQgryr